Bone Grafts and Substitutes Market Report 2026

The bone grafts and substitutes market size has grown strongly in recent years. It will grow from $3.57 billion in 2025 to $3.79 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to rising incidence of orthopedic trauma cases, expansion of spinal fusion surgeries, growing adoption of dental bone grafting, availability of allograft materials, increased orthopedic surgical volumes.

The bone grafts and substitutes market size is expected to see strong growth in the next few years. It will grow to $4.72 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to increasing demand for advanced bone regeneration solutions, rising adoption of synthetic graft substitutes, expansion of minimally invasive orthopedic surgeries, growing focus on personalized regenerative medicine, increasing investments in biomaterial research. Major trends in the forecast period include increasing adoption of synthetic and composite bone grafts, rising use of bioactive and osteoinductive materials, growing integration of advanced biomaterials in orthopedics, expansion of minimally invasive bone repair procedures, enhanced focus on bone regeneration outcomes.

The increasing prevalence of musculoskeletal disorders such as osteoporosis and tendonitis is expected to drive the growth of the bone grafts and substitutes market in the coming years. Musculoskeletal disorders are conditions and injuries that impact the movement and structure of the human musculoskeletal system. They affect muscles, nerves, tendons, joints, cartilage, and spinal discs. Consequently, the rise in musculoskeletal disorders has led to an increased demand for bone grafts and substitutes. For example, in July 2025, the Institute for Health Transformation, an Australia-based organization focused on addressing complex health challenges through collaborative research, reported that by 2033, 7.7 million Australians aged 50 years and older are projected to have osteoporosis and osteopenia, marking a 23% increase from 2023. Therefore, the growing incidence of musculoskeletal disorders is expected to drive higher demand in the bone grafts and substitutes market.

Key companies in the bone grafts and substitutes market are concentrating on developing innovative solutions, such as antibiotic-eluting bone graft substitutes, to address the rising need for advanced, infection-resistant grafting materials. Antibiotic-eluting bone graft substitutes are biomaterials designed to repair bone defects while simultaneously releasing antibiotics to prevent postoperative infections, providing better outcomes than traditional grafts. For instance, in June 2023, BONESUPPORT, a Sweden-based medical technology company, introduced CERAMENT G, a novel antibiotic-eluting bone graft substitute. The product comes in a refined kit that is 28% smaller, features surface-sterile components for easier handling, enhances usability, and offers a longer three-year shelf life. It retains the same composition and mechanism of action as previous versions while improving environmental sustainability and surgical workflow efficiency.

In June 2023, Biocomposites, a UK-based medical technology company, acquired Artoss GmbH for an undisclosed amount. Through this acquisition, Biocomposites intends to enhance its portfolio by incorporating Artoss’ innovative NanoBone technology and research expertise, thereby improving its offerings in bone graft substitutes for orthopedic, spine, foot and ankle, and dental applications, while expanding its presence in the global bone graft market. Artoss GmbH is a Germany-based biotechnology company focused on developing and manufacturing advanced bone graft substitute products.

Major companies operating in the bone grafts and substitutes market are Medtronic plc, Stryker Corporation, Smith & Nephew, Johnson & Johnson, Zimmer Biomet, SeaSpine, Integra Lifesciences Holdings Corporation, NuVasive Inc., Orthofix Holdings Inc., Straumann, Geistlich Bio-Oss, Exabone GmbH, Mathys AG, Dentsply Sirona Inc, Arthrex Inc, Graftys, Keystone Dental, Allosource, DePuy Synthes, Wright Medical Group N.V.

North America was the largest region in the bone grafts and substitutes market in 2025. The regions covered in the bone grafts and substitutes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bone grafts and substitutes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the bone grafts and substitutes market by increasing costs of imported biomaterials, processing equipment, sterilization systems, and surgical-grade raw materials. Hospitals and surgical centers in North America and Europe are most affected due to reliance on imported synthetic graft materials and biologics, while Asia-Pacific faces cost pressure on medical material imports. These tariffs are increasing procedure costs and supply chain complexity. However, they are also encouraging domestic biomaterial manufacturing, regional processing capabilities, and innovation in cost-effective bone graft substitutes.

The bone grafts and substitutes market research report is one of a series of new reports that provides bone grafts and substitutes market statistics, including bone grafts and substitutes industry global market size, regional shares, competitors with a bone grafts and substitutes market share, detailed bone grafts and substitutes market segments, market trends and opportunities, and any further data you may need to thrive in the bone grafts and substitutes industry. This bone grafts and substitutes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bone grafts and substitutes involve a procedure in which bone defects are filled using either bone grafts or bone graft substitutes. Bone abnormalities requiring bone grafting are frequently encountered in trauma and orthopedic surgeries. Bone grafting can be defined as the integration and interlocking of donor bone tissue with the new bone formed by the recipient. It is a versatile approach that replaces lost bone tissue and promotes bone growth through natural processes. Bone grafts and substitutes are used to replace and regenerate missing bone and can also help restore proper facial contour.

The primary types of bone grafts and substitutes include allografts, synthetics, and xenografts. Allograft bone grafts and substitutes refer to tissue grafts obtained from a donor of the same species as the recipient. Allografts are often used in spinal fusion procedures. Their applications include spinal fusion, trauma repair, craniomaxillofacial reconstruction, joint reconstruction, dental bone grafting, and others, and they are utilized by various end users such as hospitals, surgical centers, and more.

The bone grafts and substitutes market consists of sales of xenograft tissue, alloplast bone graft, autograft tissue, and allograft tissue. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.